Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
RAS wild-type
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
3845
;
4893
;
3265
Related biomarkers:
Expression
Mutation
CNA
Others
‹
NRAS overexpression (4)
KRAS overexpression (2)
HRAS overexpression (2)
KRAS G13D overexpression (1)
NRAS expression (1)
KRAS expression (0)
NRAS overexpression (4)
KRAS overexpression (2)
HRAS overexpression (2)
KRAS G13D overexpression (1)
NRAS expression (1)
KRAS expression (0)
›
Associations
(17)
News
Trials
Search handles
@ArndtVogel
@Aydah_AlAwadhi
@BenWestphalen
@BrunoBockorny
@CathyEngMD
@DrBonillaOnc
@DrChoueiri
@Dr_Ivanoncologo
@Dr_R_Kurzrock
@GIcancerDoc
@HHorinouchi
@HKennecke
@JohnRTMonsonMD
@MLPOncoData
@MPishvaian
@Rndubois
@ShaalanBeg
@StephenVLiu
@SyedAAhmad5
@VanMorrisMD
@VivekSubbiah
@aparna1024
@bmassutis
@cancerassassin1
@drkpavithran
@fernandbteich
@helops79
@jgong15
@jonathanloree
@marklewismd
@p_ciracimd
@pashtoonkasi
@ramyathota1
@scottrberry
@weldeiry
@weoncologists
Search handles
@ArndtVogel
@Aydah_AlAwadhi
@BenWestphalen
@BrunoBockorny
@CathyEngMD
@DrBonillaOnc
@DrChoueiri
@Dr_Ivanoncologo
@Dr_R_Kurzrock
@GIcancerDoc
@HHorinouchi
@HKennecke
@JohnRTMonsonMD
@MLPOncoData
@MPishvaian
@Rndubois
@ShaalanBeg
@StephenVLiu
@SyedAAhmad5
@VanMorrisMD
@VivekSubbiah
@aparna1024
@bmassutis
@cancerassassin1
@drkpavithran
@fernandbteich
@helops79
@jgong15
@jonathanloree
@marklewismd
@p_ciracimd
@pashtoonkasi
@ramyathota1
@scottrberry
@weldeiry
@weoncologists
Filter by
Latest
9ms
#Tucatinib + #Trastuzumab was approved earlier this year for refractory mCRC HER 2 positive disease. Previously, we had also discussed the implications of anti-egfr therapy w/ @GIcancerDoc and @CathyEngMD in this subset + RAS WT. This study by @GIcancerDoc continues to support:… https://t.co/16FDqtJdMS (@OncBrothers)
9 months ago
HER-2 positive • RAS wild-type
|
Herceptin (trastuzumab) • Tukysa (tucatinib)
10ms
Optimal maintenance strategy following FOLFOX + anti-EGFR in RAS WT mCRC: individual patient data pooled analysis of 4 clinical trials @OncologyAdvance https://t.co/m0C5Z9Vc3S 👉Low evidence, overall FU/LV + anti-EGFR preferred maintenance, stop & go stillan option @myESMO… https://t.co/VaNKlHpNf3 (@ArndtVogel)
10 months ago
Retrospective data
|
RAS (Rat Sarcoma Virus)
|
RAS wild-type
|
5-fluorouracil • leucovorin calcium
10ms
Panitumumab plus TAS as anti-EGFR rechallenge therapy in refractory RAS WT #CRC: OS & subgroup analysis of the randomized VELO trial at #WCGIC2023 👉rechallenge with anti-EGFR seems to be effective 👉PFS improved 👉no OS benefit, but 50% crossover @WCGIC @myESMO @OncoAlert (@ArndtVogel)
10 months ago
Clinical
|
RAS wild-type
|
Vectibix (panitumumab)
10ms
#OpenAccess from @FoundationATCG Genomic landscape of clinically advanced KRAS wild-type #PancreaticCancer Approximately 8% of pancreatic cancers are KRAS wild type, and many harbor actionable alterations. https://t.co/OmpTdg0OYU (@Aiims1742)
10 months ago
Clinical • Metastases
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS wild-type • RAS wild-type
11ms
BI-2493 / BI-2865: non-covalent inhibitors, binding the inactive state of KRAS, blocked the activation of wild-type KRAS and a broad range of KRAS mutants, including G12A/C/D/F/V/S, G13C/D, V14I, L19F, Q22K, D33E, Q61H, K117N and A146V/T. @Boehringer #LCSM https://t.co/7m549MX20c (@HHorinouchi)
11 months ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS wild-type • RAS wild-type • KRAS G12A • KRAS G12 • KRAS G13 • KRAS Q61H • KRAS A146V • KRAS G13C
|
BI-2493
11ms
.@StintzingS joins us to chat about the results of the phase III FIRE-4 study designed for patients with metastatic colorectal cancer with RAS wild-type tumours. Watch the full discussion here: https://t.co/0yd9ACOnpD #ASCO2023 #Oncology #CancerCare #ColorectalCancer (@OncEd)
11 months ago
Clinical • Metastases
|
RAS (Rat Sarcoma Virus)
|
RAS wild-type
11ms
While we wait for better quality pics.. 😉 @VerastemOncolog @BanerjeeSusana @ASCO #ASCO23 RAMP201 #LGSOC #ovariancancer Phenomenal efficacy, safety data ▪︎RAF-MEK clamp avutometinib/ FAKi Defactinib. •Confirmed ORR 45% •KRASm 60% •KRAS WT 29% •(Unconfirmed ORR 52%-73%-29%) https://t.co/X6u3De05v4 (@CrozrX)
11 months ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS wild-type • RAS wild-type
|
avutometinib (VS-6766) • defactinib (VS-6063)
11ms
Dr. Osumi from the super productive Japanese GOZILA team investigating the incidence and predictors for Neo RAS wild-type mCRC -NGS in CRC not static after all! #ASCO2023 #ASCO23 @KristenCiombor (@OncLive)
11 months ago
Next-generation sequencing
|
RAS (Rat Sarcoma Virus)
|
RAS wild-type
11ms
@StintzingS PhIII FIRE-4 #1L RAS WT #mCRC 13% RAS MT/7% BRAF MT in liquid bx despite WT on tissue predicts ORR, PFS, OS w/double WT on baseline liquid+tissue NGS w/FOLFIRI+cetux +/- switch maint. 19.4% emerging RAS mt w/cont cetux med 48.3 wks exposure w/no OS impact @OncoAlert (@jgong15)
11 months ago
Next-generation sequencing
|
BRAF (B-raf proto-oncogene) • RAS (Rat Sarcoma Virus)
|
RAS wild-type
|
5-fluorouracil • irinotecan • leucovorin calcium
11ms
Now at #ASCO23: Dr. @gandhi_shipra on DC vaccine/pembro to address unmet need for patients with asymptomatic brain-metastatic #TNBC or HER2+ #breastcancer, and Dr. Rachel Frascati sharing promising findings on CIMAvax/nivo for patients with wild-type KRAS #NSCLC #lungcancer (@RoswellPark)
11 months ago
Clinical • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase)
|
KRAS wild-type • RAS wild-type
|
Keytruda (pembrolizumab) • Opdivo (nivolumab)
11ms
Dr. Raghav presenting awaiting data from DESTINY CRC02 in HER2+ mCRC; different doses of trastuzumab deruxtecan explored, and pts with RAS wt/mutant tumors both included #ASCO2023 #ASCO23 @KristenCiombor (@OncLive)
11 months ago
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • RAS (Rat Sarcoma Virus)
|
RAS mutation • RAS wild-type
|
Enhertu (fam-trastuzumab deruxtecan-nxki)
11ms
A new randomized trial compares panitumumab and bevacizumab added to standard first-line chemotherapy for patients with left-sided, RAS wild-type metastatic colorectal cancer. https://t.co/OwrANFn49A @ILSONDavid #ColorectalCancer (@JWatch)
11 months ago
Clinical • Metastases
|
RAS wild-type
|
Avastin (bevacizumab) • Vectibix (panitumumab)
11ms
A new randomized trial compares panitumumab and bevacizumab added to standard first-line chemotherapy for patients with left-sided, RAS wild-type metastatic colorectal cancer. https://t.co/OwrANFn49A @ILSONDavid #ColorectalCancer (@JWatch)
11 months ago
Clinical • Metastases
|
RAS wild-type
|
Avastin (bevacizumab) • Vectibix (panitumumab)
12ms
Anti-EGFR Therapy for Left-Sided RAS Wild-type Colorectal Cancer—PARADIGM Shift @JAMAOnc https://t.co/tbZq9QsiHt (@SyedAAhmad5)
12 months ago
RAS wild-type
12ms
👇🏾Here’s a personalized Share Link – a URL providing 50 days' free access to the article🙌🏾 “Tucatinib plus trastuzumab for chemotherapy-refractory, HER2➕, RAS wild-type unresectable/metastatic colorectal cancer (MOUNTAINEER): phase 2 📚” 🙏🏽 @RueschCenter for 🔦 on our study. (@pashtoonkasi)
12 months ago
P2 data • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
RAS wild-type
|
Herceptin (trastuzumab) • Tukysa (tucatinib)
12ms
Tucatinib plus trastuzumab is a new treatment option for chemotherapy-refractory HER2-positive/RAS wild-type metastatic colorectal cancer-MOUNTAINEER https://t.co/GX61FjXMH7 (@drkpavithran)
12 months ago
Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • RAS wild-type • RAS wild-type + HER-2 positive
|
Herceptin (trastuzumab) • Tukysa (tucatinib)
12ms
#OpenAccess in @ESMO_Open Smaller panel, similar results: genomic profiling and molecularly informed therapy in #PancreaticCancer By @SivekeJ eat al https://t.co/oulUjClhIZ Reiterating the importance of chasing down KRAS wild type cases for alternative actionable drivers. (@Aiims1742)
12 months ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS wild-type • RAS wild-type
12ms
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study https://t.co/TWKHcuKxmh (@MLPOncoData)
12 months ago
Clinical • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • RAS wild-type • RAS wild-type + HER-2 positive
|
Herceptin (trastuzumab) • Tukysa (tucatinib)
12ms
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study https://t.co/OIScF6HZMS (@weldeiry)
12 months ago
Clinical • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • RAS wild-type • RAS wild-type + HER-2 positive
|
Herceptin (trastuzumab) • Tukysa (tucatinib)
12ms
🔥Tucatinib + trastuzumab for chemotherapy-refractory, HER2+, RAS WT #colorectalcancer🔥 🧐MOUNTAINEER 🌎phs-II, 117 pts @TheLancetOncol https://t.co/1b4G76uxxa ✅ORR 38% PFS 8,2 mo mOS 24 mo 👉The „next“ level for Her2 🎯💊!? -> now validation in phs-III @myESMO @OncoAlert https://t.co/lTXbE2bTTT (@ArndtVogel)
12 months ago
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
|
RAS wild-type
|
Herceptin (trastuzumab) • Tukysa (tucatinib)
12ms
🔥Tucatinib + trastuzumab for chemotherapy-refractory, HER2+, RAS WT #colorectalcancer🔥 🧐MOUNTAINEER 🌎phs-II, 117 pts @TheLancetOncol https://t.co/1b4G76uxxa ✅ORR 38% PFS 8,2 mo mOS 24 mo 👉The „next“ level for Her2 🎯💊!? -> now validation in phs-III @myESMO @OncoAlert (@ArndtVogel)
12 months ago
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
|
RAS wild-type
|
Herceptin (trastuzumab) • Tukysa (tucatinib)
12ms
👇🏾Here’s a personalized Share Link – a personalized URL providing 50 days' free access to the article🙌🏾 “Tucatinib plus trastuzumab for chemotherapy-refractory, HER2➕, RAS wild-type unresectable/metastatic colorectal cancer (MOUNTAINEER): phase 2 📚” https://t.co/CKqGOLxdlw (@pashtoonkasi)
12 months ago
Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
RAS wild-type
|
Herceptin (trastuzumab) • Tukysa (tucatinib)
12ms
🎯 Consensus molecular subtypes are prognostic & predictive #biomarkers for panitumumab/flurouraciil/folinic acid maintenance in RAS WT #ColorectalCancer in the PanaMa #ClinicalTrial ➡️ https://t.co/46LUif16kx #CRCSM @ArndtStahler (@JCO_ASCO)
12 months ago
Clinical
|
RAS (Rat Sarcoma Virus)
|
RAS wild-type
|
Vectibix (panitumumab) • leucovorin calcium
12ms
In Sydney, Australia 🇦🇺 to launch STELLAR 303 in Asia & Pacific countries. Testing XL-092+Atezolizumab in chemo refractory MSS #crcsm. Multiple endpoints to tackle including RAS wild type & site of metastasis 💫 @OncoAlert @ExelixisInc https://t.co/9HVFYIhzH4 (@AnwaarSaeed3)
12 months ago
RAS (Rat Sarcoma Virus)
|
RAS wild-type
|
Tecentriq (atezolizumab) • zanzalintinib (XL092)
1year
MORE is better?Panitumumab vs Bevacizumab and Survival in Patients With RAS Wild-type, Left-Sided Colorectal Cancer https://t.co/AWXP9I73Zu via @JAMA_current part of @JAMANetwork @Dr_M_Tejani @drzakoncology (@JohnRTMonsonMD)
1 year ago
Clinical
|
RAS (Rat Sarcoma Virus)
|
RAS wild-type
|
Avastin (bevacizumab) • Vectibix (panitumumab)
1year
Panitumumab vs Bevacizumab and Survival in Patients With RAS Wild-type, Left-Sided Colorectal Cancer https://t.co/YOHFdVjKSi via @JAMA_current part of @JAMANetwork (@bmassutis)
1 year ago
Clinical
|
RAS (Rat Sarcoma Virus)
|
RAS wild-type
|
Avastin (bevacizumab) • Vectibix (panitumumab)
1year
What about right sided RAS wild type dMMR mCRC? (@OFDM_FSK)
1 year ago
RAS (Rat Sarcoma Virus)
|
MSI-H/dMMR • RAS wild-type
1year
🔥BRAF-Driven Pancreatic Cancer: Prevalence, Molecular Features &Therapeutic Opportunities @AACR https://t.co/lRnVm3qUQ9 👉enriched in KRAS WT (10% of cases) 👉V600E , N486-P490 deletions & fusions (2-4%) 👉💊🎯for BRAFi, MEKi & combinations.. case reports.. @myESMO @OncoAlert (@ArndtVogel)
1 year ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600 • KRAS wild-type • RAS wild-type
1year
@smitha42 very elegantly shared the data and her thoughts about treating left sided RAS Wild type mCRC! #GDUGI23 @NVijayvergiaMD @SoniaKupfer @CathyEngMD @GreatDebatesCME (@helops79)
1 year ago
RAS (Rat Sarcoma Virus)
|
RAS wild-type
1year
Great talk by @NVijayvergiaMD #GDUGI23 on the debate of the best regimen for left-sided RAS wild type mCRC! @GreatDebatesCME @CathyEngMD @smitha42 @SoniaKupfer (@helops79)
1 year ago
RAS (Rat Sarcoma Virus)
|
RAS wild-type
1year
The immune contexture of younger onset #PancreaticCancer is also quite distinct (based on bulk transcriptome profiling & deconvolution). The enrichment for RAS WT tumors & alternative drivers is a consistent finding in this age group. @PancPathologist https://t.co/RYtqjsWmir (@Aiims1742)
1 year ago
RAS (Rat Sarcoma Virus)
|
RAS wild-type
1year
Preprint using @carisls multi-omics profiling data by @DrJashDatta et al reports how young onset #PancreaticCancer is distinct at genomic & transcriptomic level from “usual” age of onset disease. https://t.co/kDtAFdmmEm Higher prevalence of KRAS WT disease & alternative drivers. (@Aiims1742)
1 year ago
Preprint
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS wild-type • RAS wild-type
1year
A 7-5 📌 In RAS WT CRC patients, testing for RAS mutations at progression on tx with EGFRi is imp--these indicate resistant clones 📌With EGFRi re-challenge after the resistant clones have disappeared, EGFRi can work again! https://t.co/d5OzE0Jezz #CRCTrialsChat @OncoAlert (@jonathanloree)
1 year ago
Clinical
|
RAS (Rat Sarcoma Virus)
|
EGFR mutation • RAS mutation • RAS wild-type
1year
#PostTest Q2️⃣ #TumorBoardTuesday 👉🏽 Free CME (AMA & MOC) 🔗https://t.co/CRWgzGDAf7 🔬Path results for 62yo 👨🏾🦳 with left-sided, metastatic #ColonCancer (unresectable liver mets) who has undergone 1 cycle of FOLFOX: disease is KRAS wild type 🧐What would you add to tx regimen? (@RischZack)
1 year ago
Metastases
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS wild-type • RAS wild-type
|
5-fluorouracil • leucovorin calcium
1year
16/22 #TumorBoardTuesday #GI23 👩🏻🏫Mini tweetorial 11👨🏻🏫 ✨VELO 📌EGFR rechallenge 📍Ph II RCT 62 pts: RAS WT mCRC on 3L; prior EGFR response & ≥4 mos EGFR break TAS-102 v TAS -102 + PAM mPFS: 4 mos💪🏽B v 2.5 mos💪🏽A (HR): 0.48; 95% CI 0.28-0.82; P = 0.007) 📚https://t.co/cUbSoaicVG (@RischZack)
1 year ago
Clinical
|
EGFR (Epidermal growth factor receptor) • RAS (Rat Sarcoma Virus)
|
RAS wild-type
|
Lonsurf (trifluridine/tipiracil)
1year
@EileenMOReilly dawn of #KRAS inh’s beyond #G12C, young onset #PDAC w/signal of KRAS WT, #KRAS WT #pancsm exquisitely targetable, & building on #POLO maintenance concept in #DDR #PancreaticCancer Now at @CSCancerCenter 4th Annual GI Tumor conf https://t.co/7s8rEqg0r4 @OncoAlert (@jgong15)
1 year ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12C • KRAS wild-type • RAS wild-type • KRAS G12
1year
Bev or antiEGFRs as upfront treatment of RAS wt mCRC patients? The answer is in the primary side ➡️ here our updated meta-analyses https://t.co/RLMZpgDqiE #oncotwitting #mCRC @IlBuonRossini @ChiaraCrem1 (@boccaccina)
1 year ago
Clinical
|
RAS (Rat Sarcoma Virus)
|
RAS wild-type
1year
Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients https://t.co/EWxWFq2XVv (@p_ciracimd)
1 year ago
Clinical • Metastases
|
RAS (Rat Sarcoma Virus)
|
RAS wild-type
1year
Today, the #FDA granted accelerated approval to tucatinib & trastuzumab for patients with RAS wild-type HER2 #mCRC. Here, Tanios S. Bekaii-Saab, MD, FACP, discusses what to expect if data from the MOUNTAINEER-03 study are positive. @GIcancerDoc @MayoClinic https://t.co/sDCamJD51Y (@TargetedOnc)
1 year ago
Clinical • FDA event
|
HER-2 (Human epidermal growth factor receptor 2) • RAS (Rat Sarcoma Virus)
|
RAS wild-type
|
Herceptin (trastuzumab) • Tukysa (tucatinib)
1year
Panitumumab Plus mFOLFOX6 Improves Survival in RAS Wild-Type mCRC https://t.co/AHd88wLylk vía @onclive (@dr_javr)
1 year ago
RAS (Rat Sarcoma Virus)
|
RAS wild-type
|
5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • leucovorin calcium
1year
L sided mCRC RAS WT, Her2 FISH positive. How do you plan to sequence Rx outside CT? A. AntiEGFR upfront & Tucatinib/Trast ≥ 2L (as approved)? B. Avoid AntiEGFR & would consider using Tuc/Tras sooner? #crcsm @BijoyTelivala @RenoHemonc @HosseinTaghiz11 @OncoAlert @aparna1024 (@OncBrothers)
1 year ago
HER-2 (Human epidermal growth factor receptor 2) • RAS (Rat Sarcoma Virus)
|
RAS wild-type
|
Tukysa (tucatinib)
1year
Absolutely critical not to miss KRAS wildtype #PancreaticCancer as this subgroup (of differing size) often has valuable targeted treatment options available to them. #pancsm 💜 (@BenWestphalen)
1 year ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS wild-type • RAS wild-type
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login